Skip to main content

Readying For a Biotech Bounce With XBI

The SPDR S&P Biotech ETF (XBI) and rival biotechnology ETFs are coming off the third quarter and have recently been beset by outflows, but some market observers believe the group offers rebound potential. The biotech segment and broader healthcare sector have also underperformed the broader...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.